Mutant Dx2018-01-08T21:20:17+00:00

Oncology Alert:
“The MutantDx Liquid Biopsy now enables cancer to be screened, diagnosed and cured before symptoms ever develop.”

Dr. Roger Hodkinson, CEO, MutantDx

MutantDx will be attending
JP Morgan Week &
BioWeekSF events
in San Francisco,
Jan. 6-12, 2018.

We look forward to
meeting you there!


Kenn Bur
Director, Investor Relations

780.233.1829 (mobile)

Corporate Chart

Bio-ID Diagnostic Inc.

• Canadian holding company
for MultiGEN patents

MultiGEN Diagnostics Inc.

• 100 per cent subsidiary

• California-registered company

MutantDx (Newco)

• 100 per cent subsidiary

• Liquid Biopsy Company
using MultiGEN patents

MutantDx has eliminated all
commercialization barriers
for the Liquid Biopsy.

Dr. Roger Hodkinson, CEO of Mutant Dx
Time: 3:10

MutantDx Video Clips:

MutantDx Will Revolutionize Cancer Screening
Play video clip

MutantDx Eliminates Barriers for Commercial Liquid Biopsy
Play video clip

MutantDx Can Identify DNA in Femtogram Concentration
Play video clip

MutantDx Presentation click to view